{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:56:16Z","timestamp":1648774576296},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00106-020-00955-5","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T12:03:19Z","timestamp":1602590599000},"page":"278-284","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deeskalationsstrategien f\u00fcr die Radiochemotherapie HPV-positiver Oropharynxkarzinome: Pro und Kontra"],"prefix":"10.1007","volume":"69","author":[{"given":"A.","family":"R\u00fchle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. H.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"955_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang\u00a0KK, Harris\u00a0J, Wheeler\u00a0R et\u00a0al (2010) Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N\u00a0Engl J Med 363:24\u201335","journal-title":"N Engl J Med"},{"key":"955_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cncr.31816","volume":"125","author":"JM Bauml","year":"2019","unstructured":"Bauml\u00a0JM, Vinnakota\u00a0R, Park\u00a0AYH et\u00a0al (2019) Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: an analysis of Veterans Health Affairs data. Cancer 125:406\u2013415","journal-title":"Cancer"},{"key":"955_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","volume":"350","author":"J Bernier","year":"2004","unstructured":"Bernier\u00a0J, Domenge\u00a0C, Ozsahin\u00a0M et\u00a0al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N\u00a0Engl J Med 350:1945\u20131952","journal-title":"N Engl J Med"},{"key":"955_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.radonc.2015.10.014","volume":"118","author":"W Budach","year":"2016","unstructured":"Budach\u00a0W, Bolke\u00a0E, Kammers\u00a0K et al (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol 118:238\u2013243","journal-title":"Radiother Oncol"},{"key":"955_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","volume":"18","author":"AM Chen","year":"2017","unstructured":"Chen\u00a0AM, Felix\u00a0C, Wang\u00a0P\u2011C et al (2017) Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a\u00a0single-arm, phase 2\u00a0study. Lancet Oncol 18:803\u2013811","journal-title":"Lancet Oncol"},{"key":"955_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2015.08.033","volume":"93","author":"BS Chera","year":"2015","unstructured":"Chera\u00a0BS, Amdur\u00a0RJ, Tepper\u00a0J et al (2015) Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 93:976\u2013985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"955_CR7","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/cncr.31338","volume":"124","author":"BS Chera","year":"2018","unstructured":"Chera\u00a0BS, Amdur\u00a0RJ, Tepper\u00a0JE et al (2018) Mature results of a\u00a0prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 124:2347\u20132354","journal-title":"Cancer"},{"key":"955_CR8","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.19.00186","volume":"37","author":"JA Contreras","year":"2019","unstructured":"Contreras\u00a0JA, Spencer\u00a0C, Dewees\u00a0T et al (2019) Eliminating postoperative radiation to the pathologically node-negative neck: long-term results of a\u00a0prospective phase II study. J\u00a0Clin Oncol 37:2548\u20132555","journal-title":"J Clin Oncol"},{"key":"955_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper\u00a0JS, Pajak\u00a0TF, Forastiere\u00a0AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N\u00a0Engl J Med 350:1937\u20131944","journal-title":"N Engl J Med"},{"key":"955_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.radonc.2020.01.016","volume":"144","author":"R Fietkau","year":"2020","unstructured":"Fietkau\u00a0R, Hecht\u00a0M, Hofner\u00a0B et al (2020) Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel\/cisplatin to standard radiotherapy with fluorouracil\/cisplatin: the pacCis-trial. Radiother Oncol 144:209\u2013217","journal-title":"Radiother Oncol"},{"key":"955_CR11","doi-asserted-by":"publisher","unstructured":"Freitag J, Wald T, Kuhnt T et al (2020) Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma. Cancer. https:\/\/doi.org\/10.1002\/cncr.32667","DOI":"10.1002\/cncr.32667"},{"key":"955_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison\u00a0ML, Trotti\u00a0AM, Harris\u00a0J et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a\u00a0randomised, multicentre, non-inferiority trial. Lancet 393:40\u201350","journal-title":"Lancet"},{"key":"955_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00066-019-01546-2","volume":"196","author":"E Haehl","year":"2020","unstructured":"Haehl\u00a0E, Nicolay\u00a0NH (2020) Omission of postoperative radiation to pathologically tumor-free cervical lymphatic pathway: long-term results of a\u00a0prospective phase II study. Strahlenther Onkol 196:101\u2013103","journal-title":"Strahlenther Onkol"},{"key":"955_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/ije\/dyp350","volume":"39","author":"JE Heck","year":"2010","unstructured":"Heck\u00a0JE, Berthiller\u00a0J, Vaccarella\u00a0S et\u00a0al (2010) Sexual behaviours and the risk of head and neck cancers: a\u00a0pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 39:166\u2013181","journal-title":"Int J Epidemiol"},{"key":"955_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ijrobp.2010.08.031","volume":"82","author":"SH Huang","year":"2012","unstructured":"Huang\u00a0SH, Perez-Ordonez\u00a0B, Liu\u00a0FF et al (2012) Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82:276\u2013283","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"955_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers11010015","volume":"11","author":"A Karabajakian","year":"2018","unstructured":"Karabajakian\u00a0A, Gau\u00a0M, Reverdy\u00a0T et\u00a0al (2018) Induction chemotherapy in head and neck squamous cell carcinoma: a question of belief. Cancers 11:15","journal-title":"Cancers"},{"key":"955_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/hed.10367","volume":"26","author":"MA List","year":"2004","unstructured":"List\u00a0MA, Rutherford\u00a0JL, Stracks\u00a0J et\u00a0al (2004) Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck 26:163\u2013170","journal-title":"Head Neck"},{"key":"955_CR18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.19.00463","volume":"37","author":"DJ Ma","year":"2019","unstructured":"Ma\u00a0DJ, Price\u00a0KA, Moore\u00a0EJ et al (2019) Phase II evaluation of aggressive dose de-escalation for Adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J\u00a0Clin Oncol 37:1909\u20131918","journal-title":"J Clin Oncol"},{"key":"955_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","volume":"35","author":"S Marur","year":"2017","unstructured":"Marur\u00a0S, Li\u00a0S, Cmelak\u00a0AJ et al (2017) E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly Cetuximab in patients with HPV-associated Resectable squamous cell carcinoma of the Oropharynx- ECOG-ACRIN cancer research group. J\u00a0Clin Oncol 35:490\u2013497","journal-title":"J Clin Oncol"},{"key":"955_CR20","doi-asserted-by":"publisher","first-page":"20140543","DOI":"10.1259\/bjr.20140543","volume":"87","author":"R Mazzola","year":"2014","unstructured":"Mazzola\u00a0R, Ricchetti\u00a0F, Fiorentino\u00a0A et al (2014) Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment. Br J Radiol 87:20140543\u201320140543","journal-title":"Br J Radiol"},{"key":"955_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna\u00a0H, Robinson\u00a0M, Hartley\u00a0A et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51\u201360","journal-title":"Lancet"},{"key":"955_CR22","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/hed.24829","volume":"39","author":"M Mifsud","year":"2017","unstructured":"Mifsud\u00a0M, Eskander\u00a0A, Irish\u00a0J et\u00a0al (2017) Evolving trends in head and neck cancer epidemiology: Ontario, Canada 1993\u20132010. Head Neck 39:1770\u20131778","journal-title":"Head Neck"},{"key":"955_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.oraloncology.2019.06.021","volume":"95","author":"K Misiukiewicz","year":"2019","unstructured":"Misiukiewicz\u00a0K, Gupta\u00a0V, Miles\u00a0BA et al (2019) Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the Quarterback trial. Oral Oncol 95:170\u2013177","journal-title":"Oral Oncol"},{"key":"955_CR24","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","volume":"20","author":"AC Nichols","year":"2019","unstructured":"Nichols\u00a0AC, Theurer\u00a0J, Prisman\u00a0E et al (2019) Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 20:1349\u20131359","journal-title":"Lancet Oncol"},{"key":"955_CR25","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12885-015-1598-x","volume":"15","author":"W Owadally","year":"2015","unstructured":"Owadally\u00a0W, Hurt\u00a0C, Timmins\u00a0H et al (2015) PATHOS: a\u00a0phase II\/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer 15:602","journal-title":"BMC Cancer"},{"key":"955_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon\u00a0JP, Le Maitre\u00a0A, Maillard\u00a0E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346\u00a0patients. Radiother Oncol 92:4\u201314","journal-title":"Radiother Oncol"},{"key":"955_CR27","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/ijc.22355","volume":"120","author":"N Reimers","year":"2007","unstructured":"Reimers\u00a0N, Kasper\u00a0HU, Weissenborn\u00a0SJ et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731\u20131738","journal-title":"Int J Cancer"},{"key":"955_CR28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s00066-019-01527-5","volume":"195","author":"A Ruhle","year":"2019","unstructured":"Ruhle\u00a0A, Nicolay\u00a0NH (2019) Dose de-escalation during adjuvant chemoradiotherapy of HPV-associated oropharyngeal squamous cell carcinoma: the MC1273 phase II study. Strahlenther Onkol 195:1110\u20131112","journal-title":"Strahlenther Onkol"},{"key":"955_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdy522","volume":"30","author":"TY Seiwert","year":"2019","unstructured":"Seiwert\u00a0TY, Foster\u00a0CC, Blair\u00a0EA et al (2019) OPTIMA: a\u00a0phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol 30:297\u2013302","journal-title":"Ann Oncol"},{"key":"955_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00066-019-01568-w","volume":"196","author":"J Von Der Gr\u00fcn","year":"2020","unstructured":"Von Der Gr\u00fcn\u00a0J, Balermpas\u00a0P (2020) Radiotherapy with cetuximab or cisplatin for squamous cell carcinoma of the head and neck-what should be preferred? Strahlenther Onkol 196:197\u2013199","journal-title":"Strahlenther Onkol"},{"key":"955_CR31","doi-asserted-by":"publisher","unstructured":"W\u00fcrdemann N, Wagner S, Sharma SJ et\u00a0al (2017) Prognostic impact of AJCC\/UICC 8th edition new staging rules in oropharyngeal squamous cell carcinoma. Front Oncol 7. https:\/\/doi.org\/10.3389\/fonc.2017.00129","DOI":"10.3389\/fonc.2017.00129"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-020-00955-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-020-00955-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-020-00955-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T09:05:29Z","timestamp":1634115929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-020-00955-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1007\/s00106-020-00955-5","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"3 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0R\u00fchle und N.\u00a0H. Nicolay geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}